EGFR-IN-109, identified by its CAS number 3019971-97-9, is a small molecule inhibitor specifically targeting the epidermal growth factor receptor (EGFR). This compound is part of a class of drugs designed to interfere with the signaling pathways that promote cell proliferation and survival in cancer cells. Characteristically, EGFR-IN-109 exhibits high selectivity for the EGFR tyrosine kinase domain, which is crucial in various cancers, particularly non-small cell lung cancer and head and neck cancers. The compound's mechanism of action involves binding to the ATP-binding site of the receptor, thereby inhibiting its phosphorylation and subsequent activation. This inhibition can lead to reduced tumor growth and enhanced apoptosis in EGFR-dependent tumors. Additionally, EGFR-IN-109 may possess favorable pharmacokinetic properties, including good oral bioavailability and a manageable safety profile, making it a candidate for further clinical evaluation. As with many targeted therapies, ongoing research is essential to fully understand its efficacy, potential resistance mechanisms, and optimal therapeutic contexts.

EGFR-IN-109

3019971-97-9: EGFR-IN-109, identified by its CAS number 3019971-97-9, is a small molecule inhibitor specifically targeting the epidermal growth factor receptor (EGFR). This compound is part of a class of drugs designed to interfere with the signaling pathways that promote cell proliferation and survival in cancer cells. Characteristically, EGFR-IN-109 exhibits high selectivity for the EGFR tyrosine kinase domain, which is crucial in various cancers, particularly non-small cell lung cancer and head and neck cancers. The compound's mechanism of action involves binding to the ATP-binding site of the receptor, thereby inhibiting its phosphorylation and subsequent activation. This inhibition can lead to reduced tumor growth and enhanced apoptosis in EGFR-dependent tumors. Additionally, EGFR-IN-109 may possess favorable pharmacokinetic properties, including good oral bioavailability and a manageable safety profile, making it a candidate for further clinical evaluation. As with many targeted therapies, ongoing research is essential to fully understand its efficacy, potential resistance mechanisms, and optimal therapeutic contexts.

EGFR-IN-109 (compound 4), an EGFR inhibitor, displays IC 50 values of 25.8 nM for EGFR WT and 182.3 nM for EGFR T790M. This compound halts the growth of cancer cells at the G2/M phase and triggers both early and late apoptosis. It is applicable in cancer research [1].

CAS 3019971-97-9

EGFR-IN-109

EGFR-IN-109

Ref: TM-T86360